We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >
Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development. Learn more >
From 2007 until 2014, the Lausanne site served as a Clinical Trial Unit (CTU) of the HIV Vaccine Trial Network (HVTN) and beginning in 2014, it serves as a Clinical Research Site (CRS) affiliated with the Seattle CTU. The Lausanne site operates within the Vaccine and Immunotherapy Center (VIC) that was created in 2001 by Prof. Giuseppe Pantaleo, MD, head of the Service of Immunology and Allergy at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. Read More.
Antibodies that are able to adhere to the outer shell of HIV can inactivate the virus, and potentially stop infection before it starts. However, HIV is one of the most changeable viruses discovered to date, and the strains in circulation vary widely. An ideal vaccine against HIV would produce antibodies that could inactivate all HIV strains, but the reality is that antibodies against one strain usually don’t work against others. Read more >
We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >
Getting the right test will prevent an incorrect diagnosis of HIV. Your study site or VISP Testing Service can provide the right test. Visit our frequently asked questions for more information.